|
NSABP C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease. |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Exelixis; Merck; Novartis; Pfizer; QED Therapeutics; Taiho Pharmaceutical |
Speakers' Bureau - BMS; Daiichi Sankyo/Astra Zeneca; Merck; Pfizer; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Pfizer; Tempus |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Seagen (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Exact Sciences |
Stock and Other Ownership Interests - Exact Sciences |
|
|
Employment - Exact Sciences |
Leadership - Cancer Prevention Movement |
Stock and Other Ownership Interests - Exact Sciences; LabCorp |
Travel, Accommodations, Expenses - Exact Sciences |
|
|
Research Funding - epizyme (Inst); MedImmune (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Exact Sciences |
Leadership - Exact Sciences |
Stock and Other Ownership Interests - Exact Sciences |
|
|
Research Funding - Genentech (Inst) |